QPPV.COM KNOWLEDGE ASSESSMENT

Somatrogon: Classification, Mechanism, Growth Hormone Use and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Somatrogon: Classification, Mechanism, Growth Hormone Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which follow-up information is most relevant when intracranial hypertension is suspected during somatrogon therapy?
Question 2 of 10 Which record structure would best support longitudinal aggregate review of somatrogon benefit-risk?
Question 3 of 10 A child receiving somatrogon develops recurrent severe headaches with vomiting and visual disturbance. Which safety concern should receive priority?
Question 4 of 10 A caregiver reports administering the weekly dose every week, but the prescribed dose in a heavier child requires two injections. Device review shows that only one injection was repeatedly given. How should this be interpreted?
Question 5 of 10 Why can recurrent injection-site reactions be pharmacovigilance-relevant even when they are medically non-serious?
Question 6 of 10 Which description best characterises somatrogon?
Question 7 of 10 A child gains substantial weight but continues receiving the same weekly somatrogon dose and subsequently has poor growth velocity. Which explanation should be considered before concluding that the medicine has lost efficacy?
Question 8 of 10 A caregiver reports that a weekly somatrogon dose was missed. Which additional information is most important for initial pharmacovigilance assessment?
Question 9 of 10 Which outcome measure is generally more informative than a single height measurement when evaluating long-term response to somatrogon?
Question 10 of 10 Why is the timing of an IGF-1 sample particularly relevant during somatrogon treatment?

Select an answer to continue.

QPPV.com